MedPath

Understanding Components of Mind-body Exercise for Physical Activity Engagement in Metabolic Syndrome

Not Applicable
Recruiting
Conditions
Metabolic Syndrome
Interventions
Other: Exercise
Other: Mindful attention
Other: Exercise with mindful attention
Registration Number
NCT05242640
Lead Sponsor
Beth Israel Deaconess Medical Center
Brief Summary

The aim of this study is to assess the feasibility and acceptability (e.g., enrollment, adherence, retention, acceptability of procedures and interventions) of a pilot factorial study design that will help elucidate components of mind-body exercise interventions. The study involves completing a walking program, a mindful attention program, a walking program that includes mindful attention, or no program at all. A "pilot" study is a smaller study that helps researchers to understand whether the study design can be carried out and what participants think about the study.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Metabolic syndrome, defined as meeting 3 or more of the following criteria in the last 12 months at the time of medical record review: (a) BMI ≥ 25; (b) fasting glucose ≥ 100 [5.6 mmol/L] or A1C ≥ 5.7 or medications; (c) blood pressure ≥ 130 systolic or ≥ 85 diastolic or medications; (d) triglycerides ≥ 150 or 1.7 mmol/L or medications; (e) or HDL < 40mg/ dL for men and 50mg/dL for women or medications;
  • insufficiently active, defined as a score ≤ 23 (moderate-to-strenuous units) on Godin-Shepard Leisure-Time Physical Activity Questionnaire;
  • age 18-70 years;
  • given medical clearance for moderate-intensity exercise and exercise stress testing by their primary care physician (PCP);
  • access to a device with internet and videoconferencing capabilities
Exclusion Criteria
  • current diagnosis of any of the following: (a) coronary artery disease or other chronic heart diseases (e.g., heart failure) in which exercise would be contraindicated or that would preclude HRV analyses (e.g., some arrhythmias); (b) any diabetes; (c) chronic obstructive pulmonary disease or other severe lung dysfunction (e.g., severe asthma); (d) severe cognitive impairment
  • >2 self-reported classes or self-guided mindfulness or mindful movement sessions per week in past 3 months
  • self-reported inability to speak and read in English
  • current beta blocker or calcium channel blocker medication
  • uncontrolled hypertension, defined as resting blood pressure ≥ 150 systolic or ≥ 90 diastolic in the last 6 months
  • self- or physician-reported contraindications for exercise (e.g., severe balance impairment, musculoskeletal restrictions)

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Arm && Interventions
GroupInterventionDescription
ExerciseExercise16 sessions over 8 weeks (2x/week) of moderate-intensity treadmill walking
Mindful attentionMindful attention16 sessions over 8 weeks (2x/week) of mindful attention audio recordings delivered via headphones
Exercise with mindful attentionExercise with mindful attention16 sessions over 8 weeks (2x/week) of moderate-intensity treadmill walking utilizing mindful attention audio recordings delivered via headphones
Primary Outcome Measures
NameTimeMethod
Perspectives on study interventionsPost-intervention (after 8 week intervention)

Perspectives on study interventions will be assessed via exit interview

Feasibility of screening: screened to eligible ratioThrough study completion, an average of 1 year

percent of screened individuals that were determined eligible for the study

Feasibility of retention: retention at each assessment6 months

percent of enrolled participants retained at post-intervention and 3-month follow-up; determined to be feasible if greater than or equal to 70% retention at each assessment

Feasibility of interventions: attendance rates for each session6 months

percent session attendance; determined to be feasible if participants attend greater than or equal to 75% of sessions

Feasibility of survey completion: survey completion rates at each assessment6 months

percent of participants that complete surveys at post-intervention and 3-month follow-up

Acceptability of interventions6 months

Acceptability of the interventions will be assessed via overall satisfaction (1 = not at all to 10 = very much); determined to be acceptable if mean rating is greater than or equal to 7.5 across 80% of sessions

Feasibility of enrollment: eligible to enrollment ratioThrough study completion, an average of 1 year

percent of eligible individuals that enroll in the study; determined to be feasible if greater than or equal to 70% of eligible patients enroll

Acceptability of study design6 months

Acceptability of the study design will be assessed via acceptability of study procedures (1= not at all to 10 = very much); determined to be acceptable if mean rating is greater than or equal to 7.5 across 80% of sessions

Secondary Outcome Measures
NameTimeMethod
Heart rate dynamicsBaseline (week 0), post-intervention (after 8 week intervention)

Assessed via 24-hour heart rate monitoring

Emotion regulationBaseline (week 0), post-intervention (after 8 week intervention), 3 months post-intervention

Difficulties in Emotion Regulation Scale, a 36-item validated self-report measure, used to assess difficulties with emotion regulation; items are rated on a 5-point Likert scale, total scores range from 36 to 180, with higher scores reflecting greater emotion regulation difficulties. 6 subscale scores with higher scores reflecting greater emotion regulation difficulties.

Ventilatory efficiencyBaseline (week 0), post-intervention (after 8 week intervention)

Assessed via a maximal cardiopulmonary exercise test, using expired gas analysis under continuous electrocardiographic monitoring.

Positive affectBaseline (week 0), post-intervention (after 8 week intervention), 3 months post-intervention

Positive and Negative Affect Schedule, a validated self-report measure, used to assess levels of positive affect. The positive affect subscale is made up of 10 items rated on a 5-point Likert scale. Scores range from 10 to 50 with higher scores indicating greater levels of positive affect

Interoceptive awarenessBaseline (week 0), post-intervention (after 8 week intervention), 3 months post-intervention

Multidimensional Assessment of Interoceptive Awareness Scale, a 32-item validated self-report measures, used to assess levels of interoceptive awareness; items are rated on a 6-point Likert scale, total scores range from 0 to 160, with higher scores reflecting greater interoceptive awareness. 8 subscales with higher scores reflecting greater interocpetive awareness

In-session oxygen consumptionWeeks 1 and 8

Submaximal cardiopulmonary exercise testing (via standard metabolic cart)

In-session respiration rateWeeks 1 and 8

Submaximal cardiopulmonary exercise testing (via standard metabolic cart)

Self-reported physical activityBaseline (week 0), post-intervention (after 8 week intervention), 3 months post-intervention

International Physical Activity Questionnaire, a validated self-report measure, used to assess levels of physical activity; walking MET mins/week, moderate MET mins/week and vigorous MET mins/week are calculated

In-session heart rateWeeks 1 and 8

Submaximal cardiopulmonary exercise testing (via standard metabolic cart)

Self-efficacyBaseline (week 0), post-intervention (after 8 week intervention), 3 months post-intervention

Multidimensional Self-Efficacy Scale, a 9-item validated self-report measure, used to assess levels of self-efficacy; scores range from 0-90 with higher scores reflecting greater self-efficacy

Objective physical activityBaseline (week 0), post-intervention (after 8 week intervention)

7 day activity monitoring (via ActiGraph monitor) to assess minutes per week in moderate-intensity exercise

In-session ventilatory efficiencyWeeks 1 and 8

Submaximal cardiopulmonary exercise testing (via standard metabolic cart)

Trial Locations

Locations (1)

Beth Israel Deaconess Medical Center

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath